Navigation Links
Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
Date:11/4/2008

ctive earnings, revenue and earnings growth, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements, including the statements contained herein regarding anticipated trends in the Company's business, are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors and industry consolidation, outsourcing trends in the pharmaceutical and biotechnology industries, the Company's ability to manage growth and continue to attract and retain qualified personnel, the Company's ability to complete additional acquisitions and to integrate newly acquired businesses, the Company's ability to penetrate new markets, the fixed price nature of contracts and cost overruns, the loss, cancellation or delay of contracts or amendments thereto, the ability to maintain existing customer relationships or enter into new ones, the Company's sales cycle, the Company's ability to obtain financing on terms acceptable to the Company, the effects of exchange rate fluctuations, risks related to non-US operations and other factors described in the Company's filings with the Securities and Exchange Commission, including Quarterly Reports on Form 10-Q and the Annual Report on Form 10-K. No assurance can be given that the Company will be able to realize the net service revenues included in backlog and verbal awards. Kendle believes that its aggregate backlog and verbal awards are not necessarily a meaningful indicator of future results. All information in this release is current as of Nov. 4, 2008. The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.


'/>"/>

SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Kendle Named to FORTUNE List of 100 Fastest-Growing Companies for 2008
2. Kendle to Present at the UBS Global Life Sciences Conference
3. Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast
4. Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress
5. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
6. Kendle Appoints Patricia Williams Vice President, Commercial Operations
7. Kendle Invites You to Attend its First Quarter 2008 Earnings Conference Call and Webcast
8. Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
9. Kendle Leaders Adopt 10b5-1 Trading Plans
10. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
11. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... (PRWEB) August 29, 2014 Intrinsic ... 13485:2003 certified, GAMP® 5 compliant imaging core lab, ... international Phase II clinical trial to assess a ... Throughout this trial, Intrinsic Imaging will provide comprehensive ... to, protocol and charter development, site qualification, site ...
(Date:8/28/2014)... 2014 “This kit has an improved extraction ... 0 to 150 ppb,” said Mark Tess, PhD, Mycotoxin Product ... to plant owners and USDA-GIPSA inspection agencies that have a ... can take place in a matter of minutes with nothing ... test the feed and grain before accepting it, but they ...
(Date:8/28/2014)... The ability for organizations to attract top ... individuals to perform at the highest of levels, are ... to compete in this post–recession era. The pharmaceutical ... the sector increasingly focuses on the importance of employee-fit ... real results on the organization's development and the innovation ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
Breaking Biology Technology:Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... Below is,updated text of Shire plc,s conference call notification. ... been updated from an earlier,release. Shire PLC (LSE: ... will announce third quarter 2007 earnings on,Thursday 1 November ... 12:00 GMT / 08:00 ET, Investor meeting and ...
... (Nasdaq: ARNA ) today reported financial results for ... in the third quarter of 2007 were $5.0 million, ... Total revenues in the first,nine months of 2007 were ... months of 2006. Revenues in the first nine months ...
... Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) today announced that ... on Wednesday, October 24,2007 after the market closes. The ... 5:00 p.m. ET, which will be open to the ... company will review,the financial results and discuss other business ...
Cached Biology Technology:Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 2Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 3Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 4Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 5Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 6Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results 7Sangamo BioSciences Announces Third Quarter 2007 Conference Call and Webcast 2
(Date:8/31/2014)... the greatest challenges in modern medicine is developing drugs ... minimal toxicity and side-effects to the patient. Such properties ... drug molecule. Ideally, the drug should have a shape ... that it binds it with high specificity. Publishing in ... synthetic amino acid that can impact the 3D structure ...
(Date:8/31/2014)... malaria diagnosis has changed very little. After taking a blood ... a glass slide, stains it with a special dye, and ... the disease. This approach gives an accurate count of how ... of disease severity but is not ideal because there ... the Singapore-MIT Alliance for Research and Technology (SMART) has now ...
(Date:8/29/2014)... recently, little has been known about what genetic changes ... of scientists, one of whom is a University of ... that genes controlling the development of the brain and ... The study was published Aug. 28 in Science ... is online at http://www.sciencemag.org/ ., The domestication of ...
Breaking Biology News(10 mins):A new synthetic amino acid for an emerging class of drugs 2A new synthetic amino acid for an emerging class of drugs 3A new way to diagnose malaria 2A new way to diagnose malaria 3New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... CAMBRIDGE, Mass. (March 16, 2011) Renowned cancer researchers ... Douglas Hanahan, Director of the Swiss Institute for Experimental ... "Hallmarks of Cancer," which has influenced the study of ... a decade. Published in January 2000, their original ...
... Global Change Biology Bioenergy proposes a new method ... in bioenergy systems. CO 2 emissions resulting from ... and environmental impact studies because bioenergy is carbon- and climate- ... combustion are sequestered by growing biomass. Its climate impact has ...
... Mass., March 16, 2011 The nutritional content of ... as owner,s perceptions about them, according to a study ... School of Veterinary Medicine at Tufts University. ... humans and petschange with aging, the Association of American ...
Cached Biology News:Whitehead scientist helps revisit 'Hallmarks of Cancer' 2Whitehead scientist helps revisit 'Hallmarks of Cancer' 3Wide variety in nutritional content found in 'senior' dog foods 2Wide variety in nutritional content found in 'senior' dog foods 3
... COOLSCOPE is an integrated digital microscope and ... computer, equipment setup, optical adjustment or software ... innovative technology, COOLSCOPE combines simplicity and advanced ... COOLSCOPE offers simultaneous viewing of a macro ...
... kit provides complete components including positive ... detection of DNA fragmentation in cultured ... of BrdU in the procedure provides ... methods. Results can be analyzed by ...
... Life Science LAS-3000 imaging system combines ... simplified user interface, providing significantly improved ... of modularities. The system is especially ... perfect standard system for Western blotting ...
... Science LAS-3000mini is a compact image ... applications, and the perfect standard system ... LAS-3000 provides significantly improved system sensitivity ... calibration standards validate that Fujis LAS-3000 ...
Biology Products: